ABLEDOCS
6.4.2021 14:03:02 CEST | Business Wire | Pressemeddelelse
AbleDocs Inc. , globalt førende udbyder af tilgængelige PDF-produkter og -services, og Diversa Docs ApS , anerkendte eksperter inden for PDF- og Web-tilgængelighedsydelser, annoncerer, at de går sammen for at blive førende i Skandinavien inden for PDF-tilgængelighedsprodukter og -services.
Med en allerede mangeårig historik for samarbejde glæder begge virksomheders grundlæggere og lederteam til at udnytte hinandens muligheder for at tilbyde større fordele til eksisterende og nye kunder.
”Diversa Docs er bredt anerkendt for deres ekspertise inden for levering af PDF/UA-kompatible og tilgængelige PDF-filer, og denne erhvervelse giver vores kombinerede kundebase mulighed for at drage fordel af oplevelsen og omfanget af vores produkter og tjenester i hele Skandinavien,” siger AbleDocs 'Præsident (GLOBAL), Adam Spencer .
”Med deres fantastiske hold og fokuserede tilgang på slutbrugeren er de den ideelle partner for AbleDocs. Med vores samlede indsats kan sammen vi drive udbredelsen af næste generations PDF-tilgængelighedstjenester og -løsninger, ”siger Vice President (SCANDINAVIA), Jens Bjerre Kirkegaard .
”Tilgængelighed har altid appelleret til mig, fordi det kombinerer et teknisk felt med et humanistisk område,” siger administrerende direktør for Diversa Docs, Asbjørn Fangel-Hansen . ”Efter at have arbejdet i 12 år i den danske offentlige sektor inden for tilgængelighed og senest som ejer af en af de førende virksomheder inden for tilgængelighed i Danmark, er jeg meget beæret over at blive en del af en af de absolut førende globale aktører, når det kommer til tilgængelige dokumenter, ”tilføjer Fangel-Hansen.
Kombinationen af AbleDocs og Diversa Docs vil udvide den globale tilstedeværelse af AbleDocs med produkter, services, udvikling af løsninger og uddannelse tilpasset til lokale forhold på 49 sprog for at sikre, at kunderne får de bedst mulige tilbud.
Om Diversa Docs
Diversa Docs ApS blev grundlagt af Lars Holm-Sørensen og Asbjørn Fangel-Hansen i 2019 som søsterselskab til Diversa ApS. Siden da har virksomheden udviklet sig til at være en af de førende i Danmark med hensyn til dokumenttilgængelighed og området generelt.
Om AbleDocs Inc.
AbleDocs blev grundlagt i 2019 som et konglomerat af udbydere af PDF-tilgængelighedstjenester og er vokset til at have aktiviteter i Canada, Danmark, Tyskland, Schweiz og USA. Grundlæggerne har mere end 150 års kombineret erfaring med tilgængelige dokumenter i og har siden udvidet sine tilbud til også at inkludere en helt ny tilgang til dokumenttilgængelighedsstrategier og løsninger til tilgængelige dokument produceret i store mængder samt test af tilgængelige dokumenter.
AbleDocs er det eneste firma i verden, der garanterer, at hver fil, de producerer, overholder gældende lovgivning for tilgængelighed og bakker det op med en garanti på $ 10.000.000.
Aktuelle produkter og services fra AbleDocs inkluderer ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord og axesPDF.
For mere information, besøg https://www.abledocs.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210406005231/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum